<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016025</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0119_AD-HERE</org_study_id>
    <secondary_id>2019-001324-35</secondary_id>
    <nct_id>NCT04016025</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers</brief_title>
  <acronym>AD-HERE</acronym>
  <official_title>Randomized Single-blind Study on the Adherence to Treatment With Topical Methylprednisolone Aceponate (Advantan®) in Different Vehicles (AD-HERE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Untersuchung der Adhärenz zur topischen Standardtherapie bei Patienten mit chronischem
      Handekzem in Abhängigkeit von der Galenik
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, parallel grouped, single-blinded (investigator), monocentric
      objective assessment of the adherence to the treatment with topical methylprednisolone
      aceponate (Advantan®) depending on the type of vehicle in patients with hand eczema treated
      according to the current Guideline.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized single-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The investigator of the study will not know in which vehicle the enrolled patient will receive the standard therapeutical drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>28 days</time_frame>
    <description>Adherence defined as percentage of patients applying at least aimed daily dose Adherence will be assumed, if
truly applicated daily dose is at least 75% of prescribed daily dose and
the individual mean number of applications per day is at least 0.85</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement 1</measure>
    <time_frame>28 days; visit 1 (day 1)</time_frame>
    <description>Hand surface [cm²]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement 2</measure>
    <time_frame>28 days; visit 1 (day 1), 2 (day 14) and 3 (day 28)</time_frame>
    <description>Weight of topical drug container [mg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual amount of topical drug</measure>
    <time_frame>28 days</time_frame>
    <description>- weight of topical drug container [mg] by hand surface [cm²] will be combined to individual amount of topical drug which will as well be the prescribed daily dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Truly applicated daily dose</measure>
    <time_frame>28 days</time_frame>
    <description>- individual amount of topical drug used [mg/cm²] by individual mean number of applications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Hand Eczema</measure>
    <time_frame>28 days; visit 1 (day 1), 2 (day 14) and 3 (day 28)</time_frame>
    <description>Hand Eczema Severity Index (HECSI) Score: 0-360 Points (Total HECSI score = Sum (E, I, V, F, S, O) X Ex (Fingertips) + Sum (E, I, V, F, S, O) X Ex (Fingers except tips) + Sum (E, I, V, F, S, O) X Ex (Palm of hands) + Sum (E, I, V, F, S, O) X Ex (Back of hands) + Sum (E, I, V, F, S, O) X Ex (Wrists))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hand Eczema</measure>
    <time_frame>28 days; visit 1 (day 1), 2 (day 14) and 3 (day 28)</time_frame>
    <description>Investigator's global Assessment (IGA) Score: 0-4 Points (0=Clear, 1=Almost clear, 2=Mild, 3=Moderate, 4=Severe)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Adherence, Patient</condition>
  <condition>Chronic Eczema</condition>
  <arm_group>
    <arm_group_label>cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with topical Methylprednisolone aceponate 0,1% cream (Advantan®) plus Basic care (Bepanthen® Sensiderm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fatty ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with topical Methylprednisolone aceponate 0,1% fatty ointment (Advantan®) plus Basic care (Bepanthen® Sensiderm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Adherence to topical standard therapy assessed</intervention_name>
    <description>Adherence defined as percentage of patients applying at least aimed daily dose</description>
    <arm_group_label>cream</arm_group_label>
    <arm_group_label>fatty ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent has been obtained.

          2. Clinical diagnosis of chronic mild-to-moderate hand dermatitis with or without atopic
             etiology or background (according to IGA: at least mild at Visit 1).

          3. Subjects (male or female) aged from 18 to 65 years.

          4. In overall good health including well controlled diseases as determined by medical
             history, physical examination, vital signs and clinical laboratory.

          5. Female subjects must be of either:

               -  non-childbearing potential, post-menopausal, or have a confirmed clinical history
                  of sterility or,

               -  childbearing potential, provided there is a confirmed negative urine pregnancy
                  test prior to exposure, to rule out pregnancy Female subjects of childbearing
                  potential must be willing to use highly effective methods of contraception to
                  avoid causing pregnancy from enrolment and until the last visit (V3).

          6. Female subjects must not be breastfeeding.

        Exclusion Criteria:

          1. females who are pregnant or breast-feeding.

          2. Systemic treatment with immunosuppressive drugs, retinoids or corticosteroids within 8
             weeks prior to randomization.

          3. Phototherapy (PUVA or UVB) on the hands within 4 weeks prior to randomization.

          4. Topical applied treatment with immunomodulators (e.g. pimecrolimus or tacrolimus) or
             corticosteroids on the hands within 2 weeks prior to randomization.

          5. Use of other treatment on the hands during the clinical trial except for the use of
             investigational medicinal product (IMP) and emollient provided by sponsor during the
             clinical trial.

          6. Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2
             weeks prior to randomization.

          7. Concurrent skin diseases on the hands and/or integument with acute flare and/or skin
             lesions within the last 8 weeks.

          8. Current diagnosis of eczema on the integument except for the hands.

          9. Current diagnosis of exfoliative dermatitis.

         10. Current diagnosis of glaucoma or cataract.

         11. Significant clinical infection on the hands which requires antibiotic treatment.

         12. Known or suspected hypersensitivity to component(s) of the IMP.

         13. Subjects with history of an immunocompromising disease (e.g. lymphoma, HIV).

         14. Former participation in this clinical trial.

         15. Current participation in any other interventional clinical trial.

         16. Subjects known or, in the opinion of the investigator, are unlikely to comply with the
             Clinical Trial Protocol (e.g. alcoholism, drug dependency or psychotic state).

         17. Close affiliation with the investigator or other employees of the trial site (e.g. a
             close relative) or persons working at LEO Pharma A/S or Bayer Consumer Care AG or
             subject is an employee of sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Elsner, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Jena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah M Gregersen, Dr. med.</last_name>
    <phone>+4915232185057</phone>
    <email>DeborahMaria.Gregersen@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Peckruhn, Dr. med.</last_name>
    <phone>+4915232185339</phone>
    <email>melanie.peckruhn@derma.uni-jena.de</email>
  </overall_contact_backup>
  <reference>
    <citation>Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, Fartasch M, Gimenez-Arnau A, Nixon R, Sasseville D, Agner T. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1-22. Review.</citation>
    <PMID>25763418</PMID>
  </reference>
  <reference>
    <citation>Torrelo A. Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol. 2017 Jun;56(6):691-697. doi: 10.1111/ijd.13485. Epub 2017 Mar 4. Review.</citation>
    <PMID>28258632</PMID>
  </reference>
  <reference>
    <citation>Schliemann S, Petri M, Elsner P. How much skin protection cream is actually applied in the workplace? Determination of dose per skin surface area in nurses. Contact Dermatitis. 2012 Oct;67(4):229-33. doi: 10.1111/j.1600-0536.2012.02119.x. Epub 2012 Jun 18.</citation>
    <PMID>22709142</PMID>
  </reference>
  <reference>
    <citation>Lee JY, Choi JW, Kim H. Determination of hand surface area by sex and body shape using alginate. J Physiol Anthropol. 2007 Jun;26(4):475-83.</citation>
    <PMID>17704626</PMID>
  </reference>
  <reference>
    <citation>Gray R, Wykes T, Gournay K. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J Psychiatr Ment Health Nurs. 2002 Jun;9(3):277-84. Review.</citation>
    <PMID>12060371</PMID>
  </reference>
  <reference>
    <citation>Ofenloch RF, Weisshaar E, Dumke AK, Molin S, Diepgen TL, Apfelbacher C. The Quality of Life in Hand Eczema Questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014 Aug;171(2):304-12. doi: 10.1111/bjd.12819. Epub 2014 Jun 18.</citation>
    <PMID>24397866</PMID>
  </reference>
  <reference>
    <citation>Agner T, Jungersted JM, Coenraads PJ, Diepgen T. Comparison of four methods for assessment of severity of hand eczema. Contact Dermatitis. 2013 Aug;69(2):107-11. doi: 10.1111/cod.12039.</citation>
    <PMID>23869730</PMID>
  </reference>
  <reference>
    <citation>Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, Holló P, Cambazard F, Lahfa M, Elsner P, Nyberg F, Svensson A, Brown TC, Harsch M, Maares J. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008 Apr;158(4):808-17. doi: 10.1111/j.1365-2133.2008.08487.x. Epub 2008 Feb 21.</citation>
    <PMID>18294310</PMID>
  </reference>
  <reference>
    <citation>Reich A, Chatzigeorkidis E, Zeidler C, Osada N, Furue M, Takamori K, Ebata T, Augustin M, Szepietowski JC, Ständer S. Tailoring the Cut-off Values of the Visual Analogue Scale and Numeric Rating Scale in Itch Assessment. Acta Derm Venereol. 2017 Jun 9;97(6):759-760. doi: 10.2340/00015555-2642.</citation>
    <PMID>28224165</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Elsner</investigator_full_name>
    <investigator_title>Prof. Dr. med. P. Elsner, Head of Dermatology, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

